Topic: influenza

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

Novavax's NanoFlu vaccine beat Sanofi's Fluzone HD in seniors in a midstage test, setting up the smaller company's shot for a move into phase 3.

Here is some other vaccine news of note for the week.

After a horrible flu season last year, more people have gotten vaccinations so far this year, according to the CDC.

The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.

Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.

Roche hopes the single-dose flu drug can squeeze out some generic competition to Tamiflu.

Here is some other vaccine news of note for the week.

While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.